Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (REGN)

Statement of Financial Position, Liabilities and Stockholders’ Equity

Difficulty: Beginner

The statement of financial position provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Regeneron Pharmaceuticals Inc., Consolidated Statement of Financial Position, Liabilities and Stockholders’ Equity

USD $ in thousands

Microsoft Excel LibreOffice Calc
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Accounts payable 218,200  178,183  134,984  140,962  99,508 
Accrued payroll and related costs 261,800  191,825  153,086  133,223  92,778 
Accrued clinical trial expense 142,200  120,891  91,753  88,297  41,555 
Accrued sales-related charges, deductions, and royalties 182,700  194,542  159,985  195,986  133,085 
Income taxes payable 20,800  227  235,776  —  — 
Other accrued expenses and liabilities 164,600  129,410  103,512  85,644  117,302 
Accrued expenses and other current liabilities 772,100  636,895  744,112  503,150  384,720 
Capital and facility lease obligations, current portion —  —  129,557  1,789  1,353 
Deferred revenue from Sanofi, current portion 246,700  177,746  115,267  101,573  15,927 
Deferred revenue, other, current portion 205,800  142,392  116,397  51,914  58,098 
Convertible senior notes, current portion —  —  —  10,802  — 
Other current liabilities —  267  1,178  972  95,054 
Current liabilities 1,442,800  1,135,483  1,241,495  811,162  654,660 
Capital and facility lease obligations, excluding current portion 708,500  703,453  351,569  362,919  310,938 
Deferred revenue from Sanofi 279,300  379,936  503,474  582,664  72,367 
Deferred revenue, other 184,900  249,263  327,298  82,015  103,909 
Convertible senior notes, excluding current portion —  —  —  —  146,773 
Other noncurrent liabilities 361,700  152,073  100,385  115,535  40,855 
Noncurrent liabilities 1,534,400  1,484,725  1,282,726  1,143,133  674,842 
Total liabilities 2,977,200  2,620,208  2,524,221  1,954,295  1,329,502 
Preferred Stock, $.01 par value; issued and outstanding - none —  —  —  —  — 
Class A Stock, convertible, $.001 par value —  2  2  2  2 
Common Stock, $.001 par value 100  110  108  106  102 
Additional paid-in capital 3,911,600  3,512,833  3,029,993  3,099,526  2,404,118 
Retained earnings 5,254,300  2,946,733  1,748,222  852,700  255,382 
Accumulated other comprehensive income (loss) (12,300) 640  (12,840) 8,572  52,251 
Treasury Stock, at cost (396,400) (316,240) (316,240) (306,069) (169,530)
Stockholders’ equity 8,757,300  6,144,078  4,449,245  3,654,837  2,542,325 
Total liabilities and stockholders’ equity 11,734,500  8,764,286  6,973,466  5,609,132  3,871,827 

Based on: 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12).

Item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Regeneron Pharmaceuticals Inc.’s current liabilities declined from 2016 to 2017 but then increased from 2017 to 2018 exceeding 2016 level.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Regeneron Pharmaceuticals Inc.’s noncurrent liabilities increased from 2016 to 2017 and from 2017 to 2018.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Regeneron Pharmaceuticals Inc.’s total liabilities increased from 2016 to 2017 and from 2017 to 2018.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Regeneron Pharmaceuticals Inc.’s stockholders’ equity increased from 2016 to 2017 and from 2017 to 2018.